



Paris April 3, 2019: Alzheimer's Disease recurrent failures: A causal CADI™ model explains 14 key disease components!

Our CADI™ AD model that already explains 14 key disease components, is unifying opposing viewpoints while clarifying much of the inconsistency in the bibliography.

In its current state, our CADI™ AD model describes the causal mechanisms and progression of the disease, producing biomarkers that could predict and increase vigilance against AD in the early stages of its progression.*

Two forthcoming opportunities to meet and discuss the applications of Mechanisms-Based Medicine in neurology:

- *April 9-10, 2019:* BMSystems is invited by [POLEPHARMA](#), the N°1 pharmaceutical cluster in Europe, to present its neurology programs including [GEMMA* H2020](#) (Neurology/Autism & Microbiota). [POLEPHARMA DAYS OF MICROBIOMICS](#) - Translational research and applications of microbiota science.
- *May 22-23, 2019:* BMSystems will be participating to [NDD \(Neurodegenerative Drug Development\) Europe 2019](#). This is an opportunity to meet with Eli Lilly, Esai, Lundbeck, Roche, GSK, Janssen, UCB, AbbVie, Sanofi, Servier and present our neurology programs including our evaluation-ready *novel concept for Alzheimer's disease*. We will furthermore present our new CADI™ dual therapeutic program for Metabolic Syndrome and Parkinson's disease, now completed and awaiting clinical validation.

Bio-Modeling Systems, *the world's first Mechanisms-Based Medicine company*, has generated 14 successes independently validated by our clients/partners of which: a world's first in neurodegenerative diseases, 1 therapeutic spin-off, 1 exclusive out-license, 4 issued patents, 10 publications (*for all details, visit our website*).

Latest news: This year, for the United Nations [World Autism Awareness Day](#), we are happy to announce the release of the public GEMMA (Autism & Microbiota) program web site: www.gemma-project.eu. We are the integrative biology partner of [GEMMA](#) (Autism & Microbiota) program selected for 14,2 M€ H2020 E.C. funding. GEMMA has assembled a team of scientists from [EBRIS](#); [Bio-Modeling Systems](#); [Nutricia Research](#); [Medinok](#); [Euformatics](#); [Theoreo](#); [National University of Ireland Galway](#); [Azienda Sanitaria Locale Salerno](#); [Massachusetts General Hospital for Children \(teaching hospital of Harvard Medical School\)](#); [Consiglio Nazionale delle Ricerche](#); [INRA](#); [INSERM](#); [Utrecht University](#); [University of Tampere](#); [Imperial College London](#) and [John Hopkins University](#).

We warmly invite you to download our [Short corporate Presentation](#) or our [CADI™ Discovery Concept and POCs Presentation](#)

Do not hesitate to contact us for more information or any request.

Manuel Gea CEO; VP R&D IT manuel.gea@bmsystems.net



About Bio-Modeling Systems (BMSystems):

Bio-Modeling Systems, founded in 2004 and profitable since 2006, is with its operational "Augmented Intelligence" CADI™ Discovery™ platform the first and, to date, only company to successfully create in-silico heuristic models validated in-vivo that successfully create in-silico heuristic models validated in-vivo. BMSystems' models have been built by its biologists using an integrated IT solution called CADI™ (Computer Assisted Deductive Integration) and have led to discoveries and patents in the fields of infectious diseases, oncology, neurology, psychiatry, dermatology, immunology, metabolic disorders, innovative bioprocesses for industrial biotech and the creation of new companies exploiting these patents. BMSystems' models describe the biological phenomena involved in pathological states and provide novel mechanistic integrations to explain the cause of certain diseases, identify and select predictive biomarkers, offer new combinations of molecules and new therapeutic strategies, thereby contributing to the development of Mechanism-Based Medicine.

Bio-Modeling Systems, the world's first Mechanisms-Based Medicine Company, generated 14 successes independently validated by our clients/partners of which: 1 therapeutic spin-off in antibiotic resistance and 1 exclusive out-license in CNS, 4 issued patents, 10 publications.

Two new therapeutic programs in CFS-Low-grade inflammation and Parkinson's disease are ready for clinic validation.

For more information and access to presentations & publications, please visit <http://www.bmsystems.net>.

Press Contacts

BMSystems

Manuel Gea ; CEO & VP R&D IT

Phone: +336 83 06 12 72

manuel.gea@bmsystems.net